US 12,029,708

Application 17/817,927 · Granted Jul 9, 2024

Alkoxy compounds for disease treatment

Estimated expiration

October 3, 2028

1y 316d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Oct 3, 2008
+ 20 years
Oct 3, 2028
PTA +0d
Oct 3, 2028
TD applied
Oct 3, 2028
Final
Oct 3, 2028

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
August 5, 2022
Earliest effective filing
October 3, 2008
Issue date
July 9, 2024
PTA
0 days
Base expiry (before PTA)
October 3, 2028

October 3, 2008 + 20 years = October 3, 2028

  • Continuation of application 16/865,195, filed May 1, 2020, issued as US 11,446,261
  • Continuation of application 16/043,019, filed Jul 23, 2018, issued as US 10,639,286
  • Continuation of application 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
  • Continuation of application 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
  • Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
  • Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
  • Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
  • Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
  • Continuation of application 14/631,779, filed Feb 25, 2015
  • Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
  • Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
  • Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
  • Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
  • Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
  • Continuation of application 14/631,779, filed Feb 25, 2015
  • Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
  • Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
  • Continuation of application 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
  • Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
  • Continuation of application 14/631,779, filed Feb 25, 2015
  • Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
  • Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
  • Continuation of application 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
  • Continuation of application 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
  • Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
  • Continuation of application 14/631,779, filed Feb 25, 2015
  • Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
  • Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
  • Continuation of application 16/043,019, filed Jul 23, 2018, issued as US 10,639,286
  • Continuation of application 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
  • Continuation of application 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
  • Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
  • Continuation of application 14/631,779, filed Feb 25, 2015
  • Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
  • Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
  • PRO60/977,957 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term
  • PRO60/977,957 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO60/977,957 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO60/977,957 — Provisional — not used for base term
  • PRO60/977,957 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term
  • PRO60/977,957 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term
  • PRO60/977,957 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term
  • PRO60/977,957 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term
  • PRO60/977,957 — Provisional — not used for base term
  • PRO61/066,353 — Provisional — not used for base term
  • PRO61/051,657 — Provisional — not used for base term
  • PRO61/043,127 — Provisional — not used for base term
  • PRO61/060,083 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 3 filed

TD caps expiration to October 3, 2028

  • US 9,957,224· Application 13/887,243Capping patent

    Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

    Filing date
    May 3, 2013
    Earliest effective filing
    May 3, 2013
    Issue date
    May 1, 2018
    PTA
    0 days
    Calculated expiration
    May 3, 2033

    May 3, 2013 + 20y = May 3, 2033

  • US 12,029,708· Application 17/817,927(from application 17/817,927)Capping patent

    Alkoxy compounds for disease treatment

    Filing date
    Aug 5, 2022
    Earliest effective filing
    Oct 3, 2008
    Issue date
    Jul 9, 2024
    PTA
    0 days
    Calculated expiration
    Oct 3, 2028

    Continuation of 16/865,195, filed May 1, 2020, issued as US 11,446,261

    Continuation of 16/043,019, filed Jul 23, 2018, issued as US 10,639,286

    Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615

    Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615

    Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 16/043,019, filed Jul 23, 2018, issued as US 10,639,286

    Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615

    Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Oct 3, 2008 + 20y = Oct 3, 2028

  • US 11,446,261· Application 16/865,195

    Alkoxy compounds for disease treatment

    Filing date
    May 1, 2020
    Earliest effective filing
    Oct 3, 2008
    Issue date
    Sep 20, 2022
    PTA
    0 days
    Calculated expiration
    Oct 3, 2028

    Continuation of 16/043,019, filed Jul 23, 2018, issued as US 10,639,286

    Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615

    Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615

    Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496

    Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088

    Continuation of 14/631,779, filed Feb 25, 2015

    Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153

    Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071

    Oct 3, 2008 + 20y = Oct 3, 2028

  • US 7,982,071· Application 12/287,039

    Alkoxy compounds for disease treatment

    Filing date
    Oct 3, 2008
    Earliest effective filing
    Oct 3, 2008
    Issue date
    Jul 19, 2011
    PTA
    +413 days
    Calculated expiration
    Nov 20, 2029

    Oct 3, 2008 + 20y + 413d PTA = Nov 20, 2029

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/817,927 · US 12,029,708

PatentReply compiles the prosecution history behind US 12,029,708: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12029708

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.